POU2F3 and small cell lung carcinoma: There were no significant differences in OS between the atezolizumab and placebo groups stratified by NOTCH1 expression among tumors defined by high expression of POU2F3 and YAP1 (i.e., non-NE) or within the SCLC-P subset (Supplemental Figure 4, A and B).